NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Charting the Biosimilar and Biobetter Development Pipeline
http://www.reportlinker.com/p0972502/Charting-the-Biosimilar-and-Biobetter-Development-Pipeline.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical
Biosimilar development has failed to meet expectations in recent years, but that is set to change.
With a new U.S. biosimilars approval pathway imminent, and the expiration of many top-selling biologics on the horizon, existing biosimilar developers and newcomers are highly motivated to invest in the biosimilar field and are turning their attention to more complex biologics, such as monoclonal antibodies. Global sales of biologics are projected to reach $200bn in 2014 (from $138bn in 2010), making it a potentially lucrative market for biosimilar developers.
Originator, generics, and biosimilar companies alike need to be informed about the latest development trends and to know the likely patent expiration of marketed products and status of products in development. However, market intelligence has been widely dispersed, making it very difficult for companies to assess potential competition and areas of opportunity, until now.
FirstWord has gathered the very latest intelligence from BIOPHARMA, the Orange Book, literature, industry associations, company websites, and many other secondary sources to provide a single, authoritative guide to currently marketed and in-development biosimilar products.
Report Overview
In Charting the
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |